Israel-based Brainsway Ltd announced that after completing production of approximately 100 Deep TMS (transcranial magnetic stimulation) systems, it plans to “initiate US commercial sales of the device” this week. In addition, Brainsway has slated the official US marketing launch of Deep TMS for the American Psychiatric Association Annual Meeting, May 18-22, 2013, in San Francisco.
In January, the FDA approved Brainsway's proprietary DeepTMS device for the treatment of depression in patients who failed to respond to antidepressant medications in their current episode of depression.
The Deep TMS device is based on a uniquely shaped electromagnetic coil connected to a rapidly changing current supply, which produces magnetic fields capable of affecting different areas of the brain. Deep brain areas can be either excited or inhibited, depending on the frequency of the magnetic field.
Address: 5636 Lemon Ave.
Dallas TX 75209
Phone: +1 214 5203694